Prostate Cancer Clinical Trial
Trial of Quercetin, Bromelain, Rye Flower Pollen & Papain on Reducing Severity of Radiation-Induced Prostatitis
This study will assess the difference in prostatitis symptoms in men with localized prostate cancer following brachytherapy taking Q-Urol relative to placebo.
This is a Phase 2, double-blinded, placebo-controlled trial assessing the safety of Q-Urol use after brachytherapy placement in patients with localized prostate cancer. Patients will be randomized in a 1:1 ratio to receiveQ-Urol/Placebo twice daily for 6 weeks after brachytherapy placement. Questionnaires will be administered pre- and post-treatment to assess the change in prostatitis symptoms and quality of life measures. The mean values between groups will be compared.
Male subjects aged ≥ 18 years.
Men with histologically proven localized prostate adenocarcinoma, stage I - III (as defined by AJCC 8th edition), who have selected treatment with brachytherapy with or without external beam radiation, with or without androgen deprivation therapy.
Fluent in speaking and reading English.
Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1.
Adequate organ function as defined as:
Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN)
aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 3 × institutional ULN
Estimated creatinine clearance ≥ 30 mL/min by Cockcroft-Gault formula:
Males: ((140-age)×weight[kg])/(serum creatinine [mg/dL]×72)
Highly effective contraception for both male and their female partners of childbearing potential throughout the study and for at least 5 days after last study treatment administration if the risk of conception exists.
Median life expectancy ≥ 5 years as calculated by the Lee and Shonberg Index (https://eprognosis.ucsf.edu/leeschonberg.php)
Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.
Baseline AUA symptom scores > 15.
Prior diagnosis of chronic prostatitis type II through IV.
Subject has received systemic therapy intended for the treatment of prostatitis (including herbal supplements) ≤ 14 days of starting study treatment.
Subject has received a fluoroquinolone antibiotic (e.g. ciprofloxacin, norfloxacin, ofloxacin levofloxacin, etc.) ≤ 3 days of starting study treatment.
Subject is actively on anti-inflammatory medications for other medical conditions.
Subject has undergone transurethral resection of the prostate (TURP).
Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen.
History of irritable bowel syndrome, chronic fatigue syndrome, fibromyalgia, and interstitial cystitis-bladder pain syndrome (IC/BPS).
History of symptomatic hypotension, falls, or syncope
History of hypoglycemia.
Actively abusing alcohol or drugs
Subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:
Congestive heart failure
Pulmonary artery hypertension
Any clinically significant condition that requires therapy with diuretic medications for any indication other than the management of hypertension.
Other clinically significant disorders that would, in the opinion of the treating investigator, preclude safe study participation.
Known prior severe hypersensitivity to investigational product or any component in its formulations (NCI CTCAE v5.0 Grade ≥ 3).
Known allergy to pineapple or pineapple containing products.
Subjects taking prohibited medications as described in Section 7.3 A washout period of prohibited medications for a period of at least 5 half-lives or as clinically indicated should occur prior to the start of treatment.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.